Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GMMG-HD7: Isatuximab Added to RVd in Newly Diagnosed Multiple Myeloma
2024-513464-26-00Phase 3Authorised
- Sponsor
- Heidelberg University Hospital
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of isatuximab in multiple myeloma (MM) (2 arms), sponsored by Heidelberg University Hospital. Primary endpoints: Minimal residual disease (MRD) negativity after induction and Progression-free survival from 2nd randomization. Planned start Oct 2018; status: authorised.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-513464-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513464-26-00.